Begin main content

Direct Acting Antivirals for Chronic Hepatitis C genotype 1 in Select Populations: Emerging Evidence of Clinical Effectiveness and Safety

Published on: April 28, 2014
Project Number: RB0673-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the evidence for clinical effectiveness and safety of treatment with boceprevir, telaprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who are co-infected with HIV?
  2. What is the evidence for the clinical effectiveness and safety of treatment with boceprevir, telaprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have undergone liver transplant?

Key Message

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and PR combination treatments in patients with chronic hepatitis C genotype 1 who are co-infected with HIV or have undergone liver transplant.

Tags

acquired immunodeficiency syndrome, hiv, liver, liver diseases, liver transplantation, digestive system, infectious diseases